issues

November/December 2014

Download PDF

COVER

MARKET ANALYSIS – Unprecedented Uptake of Sovaldi & Tecfidera Paves the Way for New Optimism in Pharma

Joshua Owide, GlobalData’s Director of Healthcare Industry Dynamics, believes a successful drug launch is pivotal in the corporate evolution of most innovative drug companies, allowing them to sustain growth momentum, or, as is more commonplace in the age of the blockbuster patent expiration, replenish existing revenues at risk from lower-cost equivalents.

FEATURES

GLOBAL DELIVERY MARKET – Advanced Drug Delivery Systems: mAb, RNAi, & Breaking the Blood-Brain Barrier

Kevin James, Shalini Dewan, MS, Kim Lawson, and Usha Nagavarapu believe advances in understanding human biology and diseases are opening new and exciting possibilities in the biotechnology industry. R&D spending, along with increasing competition, patent expiries, and new and emerging technologies will continue to shape growth in this market for the foreseeable future.

NANOTECHNOLOGY MARKET – Nanotechnology Markets in Healthcare & Medicine

Kevin James, Jackson Highsmith, and Paul Evers report the global market for nanoparticles in the life sciences is estimated at over $29.6 billion for 2014. This market is forecast to grow to more than $79.8 billion by 2019, to register a healthy compound annual growth rate of 22%. The biggest increase will come in the area of drug delivery systems.

EXECUTIVE INTERVIEW – Exostar: Speeding the Drug Development & Delivery Process Through Secure Communities of Industry Partners

Drug Development Executive: Tom Johnson, Exostar’s Senior Director of Pharma and Life Science Solutions, discusses how Exostar’s Life Sciences Identity Hub efficiently and cost effectively brings organizations, individuals, applications, and information together to promote the external collaboration initiatives imperative to today’s drug research and development processes.

ABUSE-DETERRENT MARKET – What’s in the Pipeline? Abuse-Deterrent Products

Tugrul Kararli, PhD, MBA, Kurt Sedo, and Josef Bossart, PhD, decided it would be interesting to interrogate the PharmaCircle database and see what successes have been achieved with respect to abuse-deterrent formulations in terms of approved and pipeline products.

IMMUNOCHEMISTRY ANALYZER MARKET – Mutiplexing Technologies for Infectious Disease, Cancer, Cardiac & Autoimmune Testing Rise Above the Horizon

Divyaa Ravishankar, MS, Senior Industry Analyst at Frost & Sullivan, indicates the market has undergone a massive change from just a few vendors offering only enzyme-linked immunosorbent assay, chemiluminescent immunoassay, radioactive immunoassay, and flourescent immunoassay to also multiplex assays, such as microarrays, flow cytometry-based platforms, recombinant immunoassays, and indirect immunofluorescence assays.

DNA VACCINES MARKET – DNA Vaccines: Strategic Markets & Emerging Technologies

Kevin James, Shalini Dewan, MS, and Jon Evans, MBA, say the global market for DNA vaccines is estimated at $305.3 million for 2014 and is forecast to grow at a stellar 54.8% compound annual growth rate (CAGR) to reach $2.7 billion by 2019.

PERSONALIZED MEDICINE – Targeted, Personalized Therapy is the Future of Chronic Disease Therapeutics

The global life sciences sector is employing new research and development (R&D) and business models to cost effectively deliver innovation, value, and improved patient outcomes. With the incidence rate for..

ORPHAN DRUG MARKET – Drug Developers Drawn to Orphan Drugs Market: Financial Incentives Create Rich, Competitive Pipelines

As drug developers abandon the “blockbuster model” in favor of greater focus on drug development for rare conditions, the global orphan drugs market is becoming increasingly competitive. It is imperative that drug developers continually keep a tab of competitors’ pipelines as approval and reimbursement of new orphan drugs are highly dependent on the availability of alternative therapies.

IVD TRENDS – In Vitro Diagnostics Players Go Global as US & Europe Markets Slow Down

Despite economic and industry challenges, the global in vitro diagnostics (IVD) market is growing robustly – at double the rate of the global pharmaceutical industry (Figure 1). The market will..

INVESTMENT TRENDS – A Rise in IPOs Revive Investments for the Global Pharma & Biotech Industry

Dr. E. Saneesh, Financial Analyst at Frost & Sullivan, reports that new analysis reveals that PEVC investors in the global pharmaceutical and biotechnology industry have demonstrated maximum interest in oncology drugs, followed by anti-infective drugs and pharmaceutical contract laboratories. They also conclude the maximum pharmaceutical- and biotechnology-related PEVC deals in the US, and are expected to continue to do so in the forthcoming years.

MARKET ANALYSIS – Unprecedented Uptake of Sovaldi & Tecfidera Paves the Way for New Optimism in Pharma

Joshua Owide, GlobalData’s Director of Healthcare Industry Dynamics, believes a successful drug launch is pivotal in the corporate evolution of most innovative drug companies, allowing them to sustain growth momentum, or, as is more commonplace in the age of the blockbuster patent expiration, replenish existing revenues at risk from lower-cost equivalents.

Share This